Guest Editor(s)
-
- Dr. Ilana Chefetz, PhD
- The Hormel Institute, University of Minnesota, Austin, MN, USA.
Website | E-mail
-
- Dr. Akimasa Takahashi, MD, PhD
- The Hormel Institute, University of Minnesota, Austin, MN, USA.
Website | E-mail
-
- Dr.Imran Khan, PhD
- The Hormel Institute, University of Minnesota, Austin, MN, USA.
Website | E-mail
Special Issue Introduction
Dear colleagues,
Development of chemoresistance is one of the biggest problems in cancer causing recurrent disease and metastasis. Thus, it is crucial to elucidate molecular mechanisms and signaling pathways to develop novel targeted therapies to overcome chemoresistance.
Cell cycle abnormalities are a hallmark of cancer. The major players of the cell cycle machinery are the cyclin-dependent kinases (CDK) and the regulatory proteins called cyclins. CDK inhibitors exhibit promising results in preclinical studies blocking cell proliferation and causing cell death.
For this special issue we would like to invite original research and clinical manuscripts as well as updated reviews discussing cell cycle aberrations in cancer and novel targeted therapies that inhibit cell cycle regulators. Moreover, topics also include comparison of cell cycle inhibitors as single agents or in combination with cytotoxic drugs. In addition, this special issue will focus on the effect of CDK inhibitors on tumor microenvironment and cancer stem cells. Finally, we would like to highlight novel cell cycle-based therapies in clinical trials and combination strategies that will improve disease-free and total survival.
Looking forward to your contributions.
Submission Deadline
31 Dec 2021
Cancer Drug Resistance
cdrjournal.com
